Matrix metalloproteinase-2, -9 and tissue inhibitor metalloproteinase-1 in patients with hypertension before and after doxazosin therapy

被引:1
|
作者
Derosa G. [1 ,4 ]
Cicero A.F.G. [2 ]
D'Angelo A. [1 ]
Tinelli C. [3 ]
Ciccarelli L. [1 ]
Piccinni M.N. [1 ]
Pricolo F. [1 ]
Salvadeo S. [1 ]
Montagna L. [1 ]
Fogari E. [1 ]
Gravina A. [1 ]
Ferrari I. [1 ]
Galli S. [1 ]
Paniga S. [1 ]
Fogari R. [1 ]
机构
[1] Department of Internal Medicine and Therapeutics, University of Pavia, Pavia
[2] 'D. Campanacci' Department of Clinical Medicine and Applied Biotechnology, 'G. Descovich' Atherosclerosis Study Center, University of Bologna, Bologna
[3] Biometric Unit, IRCCS Policlinico S. Matteo, Pavia
[4] Department of Internal Medicine and Therapeutics, University of Pavia, 27100 Pavia, Piazzale C. Golgi
关键词
Hypertensive Patient; Felodipine; Antihypertensive Treatment; Doxazosin; Fast Plasma Insulin;
D O I
10.2165/00151642-200613020-00002
中图分类号
学科分类号
摘要
Background: There are conflicting data in the literature regarding both the expression pattern of the vascular metalloproteinase (MMP) system and its tissue inhibitors (TIMPs) in human hypertension and the effect of antihypertensive drugs in modifying the MMP/TIMP system. This study was designed to test the hypothesis that MMP-2, MMP-9 and TIMP-1 are altered in hypertension reflecting alterations in extracellular matrix turnover. Moreover, the aim of the study was to assess whether chronic antihypertensive treatment with doxazosin would normalise these alterations. Materials and results: We measured plasma levels and activities of MMP-2, MMP-9 and TIMP-1 in 44 hypertensive patients before and after 4 months of doxazosin treatment. MMP-2 levels and activity were significantly lower in the hypertensive group after treatment (p < 0.0001) compared with respective values before treatment. Significant decrease was also observed for MMP-9 level and activity (p < 0.0001) and for TIMP-1 (p < 0.0001) in hypertensive patients after antihypertensive treatment. Conclusions: Plasma levels and activities of MMP-2, MMP-9 and TIMP-1 are decreased in hypertensive patients after treatment compared with respective values before treatment. This may demonstrate that antihypertensive drugs modify the MMP/TIMP system, contributing to the mechanisms of vascular remodelling. © 2006 Adis Data Information BV. All rights reserved.
引用
收藏
页码:47 / 52
页数:5
相关论文
共 50 条
  • [21] Levels of Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 mRNAs in Patients with Primary Hypertension or Hypertension-induced Atherosclerosis
    Su, W.
    Gao, F.
    Lu, J.
    Wu, W.
    Zhou, G.
    Lu, S.
    [J]. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2012, 40 (03) : 986 - 994
  • [22] Expression of matrix metalloproteinase-2 and-9 and tissue inhibitor of metalloproteinase-1 and-2 in intraductal and nonintraductal growth type of cholangiocarcinoma
    Chae, KJ
    Rha, SY
    Oh, BK
    Koo, JS
    Kim, YJ
    Choi, J
    Park, C
    Park, YN
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (01): : 68 - 75
  • [23] Potential role of matrix metalloproteinase-2,-9 and tissue inhibitors of metalloproteinase-1,-2 in exudative pleural effusions
    Vatansever, S.
    Gelisgen, R.
    Uzun, H.
    Yurt, S.
    Kosar, F.
    [J]. CLINICAL AND INVESTIGATIVE MEDICINE, 2009, 32 (04): : E293 - E300
  • [24] Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension - Relationship to tissue doppler indices of diastolic relaxation
    Tayebjee, MH
    Nadar, SK
    MacFadyen, RJ
    Lip, GYH
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 2004, 17 (09) : 770 - 774
  • [25] IMBALANCE BETWEEN TISSUE INHIBITOR OF METALLOPROTEINASE-1 AND MATRIX METALLOPROTEINASE-9 AFTER CARDIOPULMONARY RESUSCITATION
    Li Jingsha
    Zhong Jingquan
    Zeng Qixian
    Liu Hongzhen
    Meng Xianglin
    Liu Donglin
    Su Guoying
    Zhang Yun
    [J]. HEART, 2011, 97
  • [26] Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 in the retinal pigment epithelium and interphotoreceptor matrix: Vectorial secretion and regulation
    Padgett, LC
    Lui, GM
    Werb, Z
    LaVail, MM
    [J]. EXPERIMENTAL EYE RESEARCH, 1997, 64 (06) : 927 - 938
  • [27] Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and-2 in type 2 diabetes
    Tayebjee, MH
    Lim, HS
    MacFadyen, R
    Lip, GYH
    [J]. DIABETES CARE, 2004, 27 (08) : 2049 - 2051
  • [28] Effect of all-trans retinoic acid on renal expressions of matrix metalloproteinase-2, matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in rats with glomerulosclerosis
    Yuan-Han Qin
    Feng-Ying Lei
    Peng Hu
    Juan Pei
    Zhen-bo Feng
    Yu-Sheng Pang
    [J]. Pediatric Nephrology, 2009, 24 : 1477 - 1486
  • [29] Effects of valsartan on matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 in atrial fibrillation patients
    裴晓阳
    潘莹
    颜雯
    胡雪松
    [J]. South China Journal of Cardiology, 2010, 11 (01) : 15 - 19
  • [30] Significance of matrix metalloproteinase-2,-11 and tissue inhibitor of metalloproteinase-1 expression in normal, hyperplastic and neoplastic endometrium
    Obokata, Akane
    Watanabe, Jun
    Nishimura, Yukari
    Arai, Tsutomu
    Kawaguchi, Miwa
    Kuramoto, Hiroyuki
    [J]. ANTICANCER RESEARCH, 2007, 27 (1A) : 95 - 105